DRP

:   disease risk prediction

GWAS

:   genome‐wide association study

OR

:   odds ratio

SNP

:   single‐nucleotide polymorphism

Genome‐wide association studies (GWASs) are increasingly uncovering the effect of genetic alterations in most of the common diseases [1](#feb412722-bib-0001){ref-type="ref"} and are considerably accelerating the commercialization of personalized medicine [2](#feb412722-bib-0002){ref-type="ref"}. One of the genetic alteration based applications for personalized medicine is disease risk prediction (DRP) [3](#feb412722-bib-0003){ref-type="ref"}, [4](#feb412722-bib-0004){ref-type="ref"}, [5](#feb412722-bib-0005){ref-type="ref"}, which has been reported to benefit individuals in terms of improving their lifestyle choices and facilitating preventive screening [3](#feb412722-bib-0003){ref-type="ref"}, [4](#feb412722-bib-0004){ref-type="ref"}, [6](#feb412722-bib-0006){ref-type="ref"}, [7](#feb412722-bib-0007){ref-type="ref"}. However, the discrepancy among DRPs of different direct‐to‐customer companies (e.g., 23andMe, Navigenics and deCODEme) has been widely reported [8](#feb412722-bib-0008){ref-type="ref"}, [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"}, [11](#feb412722-bib-0011){ref-type="ref"} and substantially limits their commercialization. Such discrepancy has been mainly attributed to the difference in the selection of single‐nucleotide polymorphism (SNP) risk factors and DRP algorithms. Although it is impossible for different DRP providers to select a palette of the same SNP risk factor markers for one type of disease, there is a high demand for the development of a general DRP algorithm.

Retrospectively, the algorithms of three DRP companies (23andMe, deCODEme and Navigenics) have notable differences in principle (as described in Data [S1](#feb412722-sup-0001){ref-type="supplementary-material"}) and are complicated and compromised [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"}. Whereas 23andMe and deCODEme transform the odds ratio (OR) of each SNP into a likelihood ratio, Navigenics transforms it into the relative risk. Thereafter, 23andMe multiplies the likelihood ratios of single genotypes by the average odds of the disease and converts these odds into risks, deCODEme multiplies the likelihood ratios by the average risk of disease, and Navigenics calculates the relative risks for all of the possible genotype combinations.

Apparently, these DRP algorithms are not suitable for generalization because of the following limitations [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"}. First, all of them require the OR values of both homozygous and heterozygous SNPs. However, the OR values for many homozygous SNPs are not available in the existing GWAS literature, and this may limit the utility of high‐risk SNPs whose OR values are available for only the heterozygous forms. Second, the DRP algorithm used by Navigenics requires a substantial amount of computer working memory [10](#feb412722-bib-0010){ref-type="ref"}. Third, the DRP algorithm used by deCODEme is apparently not normalized; that is, the calculated risk might be larger than the upper limit value of 100% under certain circumstances. It is thus highly demanding to develop a more self‐evident, robust and reliable algorithm for DRP.

Logistic regression has been widely used for risk factor identification and evaluation in general, [12](#feb412722-bib-0012){ref-type="ref"} as well as in GWASs in particular. After a regression analysis of the experimental data, the generated logistic model containing certain risk factors can be applied for DRP [5](#feb412722-bib-0005){ref-type="ref"}, [12](#feb412722-bib-0012){ref-type="ref"}, [13](#feb412722-bib-0013){ref-type="ref"}, [14](#feb412722-bib-0014){ref-type="ref"}, [15](#feb412722-bib-0015){ref-type="ref"}. However, the SNP risk factors related to a disease are usually identified in many studies by different groups of researchers; therefore, the generated logistic models in these studies are also different and would not be suitable for DRP directly. From this perspective, a method to build a general logistic model that integrates multiple SNP risk factors from multiple publications is in high demand for DRP. The algorithms explored by commercial DRP companies represent such efforts but apparently cannot meet the needs [8](#feb412722-bib-0008){ref-type="ref"}, [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"}, [11](#feb412722-bib-0011){ref-type="ref"}.

Here, we present a general approach to build a logistic model for DRP, in which multiple SNPs from multiple publications are integrated and can be promptly updated. Our model largely overcomes the aforementioned limitations of the currently used algorithms. Furthermore, we validated the model on lung cancer with Chinese individuals, illustrating its significance in preventive screening.

Materials and methods {#feb412722-sec-0002}
=====================

Data collection from the literature {#feb412722-sec-0003}
-----------------------------------

For each selected SNP, the original literature was downloaded, and the OR values for both homozygous (if available) and heterozygous SNPs were collected. SNPs with an OR \<1.15 were omitted. Then, the frequency of each SNP in Chinese individuals and all individuals was extracted from the National Center for Biotechnology Information database by searching each SNP ID (for details, refer to Table [1](#feb412722-tbl-0001){ref-type="table"}), and the lifetime risk for lung cancer in Chinese men and women was assigned according to the Chinese Cancer Registry Annual Report 2010 [16](#feb412722-bib-0016){ref-type="ref"}. These data were used by the algorithm for the regression analysis, as described in the [Results and Discussion](#feb412722-sec-0008){ref-type="sec"}.

###### 

SNPs and parameters of logistic model for lifetime risk prediction of lung cancer. NA, not available.

  SNP ID       Risk base                                      Frequency in Chinese individuals   Frequency in all individuals   OR of heterozygous SNPs                        OR of homozygous SNPs                        References                                  [a](#feb412722-note-0001){ref-type="fn"}β   [b](#feb412722-note-0001){ref-type="fn"}β~0~ calculation
  ------------ ---------------------------------------------- ---------------------------------- ------------------------------ ---------------------------------------------- -------------------------------------------- ------------------------------------------- ------------------------------------------- ----------------------------------------------------------
  rs1820453    G                                              0.239                              0.374                          1.49                                           1.65                                         [20](#feb412722-bib-0020){ref-type="ref"}   0.399                                       0.174
  rs716274     G                                              0.25                               0.438                          1.83                                           2.96                                         [20](#feb412722-bib-0020){ref-type="ref"}   0.604                                       0.294
  rs9981861    G                                              0.125                              0.332                          1.33                                           [c](#feb412722-note-0001){ref-type="fn"}NA   [21](#feb412722-bib-0021){ref-type="ref"}   0.285                                       0.036
  rs16951095   C                                              0.805                              0.917                          1.3                                            NA                                           [22](#feb412722-bib-0022){ref-type="ref"}   0.262                                       0.211
  rs1051730    T                                              0.037                              0.185                          1.31                                           NA                                           [23](#feb412722-bib-0023){ref-type="ref"}   0.270                                       0.010
  rs402710     C                                              0.733                              0.657                          1.18                                           NA                                           [24](#feb412722-bib-0024){ref-type="ref"}   0.166                                       0.121
  rs2808630    G                                              0.22                               0.211                          1.22                                           NA                                           [25](#feb412722-bib-0025){ref-type="ref"}   0.199                                       0.044
  rs7626795    G                                              0.207                              0.246                          1.16                                           NA                                           [25](#feb412722-bib-0025){ref-type="ref"}   0.148                                       0.031
  Men          [c](#feb412722-note-0001){ref-type="fn"}Risk   β~0~                               Women                          [c](#feb412722-note-0001){ref-type="fn"}Risk   β~0~                                                                                     Sum                                         0.921
  0.0562       −3.742                                         0.0256                             −4.560                                                                                                                                                                                                             

^a^In the logistic model, coefficient β for each SNP was calculated as the natural logarithm of the OR value of the heterologous SNP on the basis of Eq [(3)](#feb412722-disp-0003){ref-type="disp-formula"}. ^b^For SNP without the OR value of the homozygous form, it was the product of β and the frequency in Chinese individuals (e.g., for rs9981861, 0.285 × 0.125 = 0.036). Otherwise, it was calculated as the sum of two products contributed, respectively, by the heterozygous and homozygous SNPs \[e.g., for rs1820453, according to the Hardy‐Weinberg equilibrium, the frequencies of heterozygous and homozygous SNPs in Chinese individuals were calculated as 2 × 0.239 × (1 − 0.239) = 0.364 and 0.239 × 0.239 = 0.057, respectively, and the total contribution was calculated as ln(1.49) × 0.364 + ln(1.65) × 0.057 = 0.174\]. ^c^The average lifetime risk for lung cancer in Chinese men and women was set as 5.62% and 2.56%, respectively, according to the Chinese Cancer Registry Annual Report 2010 [16](#feb412722-bib-0016){ref-type="ref"}.
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Ethics approval and consent to participate {#feb412722-sec-0004}
------------------------------------------

The experiments in genotyping human SNPs were approved by the Ethics Committee of Third Hospital of Peking University. We confirm that our study is compliant with the 'Guidance of the Ministry of Science and Technology of China for the Review and Approval of Human Genetic Resources', and the study methodologies conformed to the standards set by the Declaration of Helsinki. The experiments were undertaken with the understanding and written consent of each subject.

Human subjects {#feb412722-sec-0005}
--------------

Patients were normally subjected to different clinical tests, including peripheral blood‐based clinical tests. The remaining blood (around at a volume of 1.5 mL) of each patient, accompanied with the information of only sex, age, smoking and clinical symptoms, was transferred by the hospital to us for DNA extraction and SNP genotyping, with the data being analyzed anonymously.

SNP genotyping {#feb412722-sec-0006}
--------------

Genomic DNA was extracted from peripheral blood by using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer\'s instructions. The primers for SNP genotyping were designed using MassArray Assay Design v4.0 according to the sequence information flanking the SNP, were synthesized by Invitrogen and were validated by MassArray Analyzer Compact. The PCR, removal of free dNTP and sequencing by MassArray Analyzer Compact (Sequenom, San Diego, CA, USA) were performed according to the manufacturer\'s instructions.

Statistics {#feb412722-sec-0007}
----------

Each sample was resequenced independently, and all of the SNP sequencing results were consistent between independent repeated experiments. Risk calculation was performed using Microsoft Excel (Microsoft, Redmond, WA, USA). A statistical analysis was performed in the [microorigin]{.smallcaps} software using the ANOVA algorithm at a significance level of 0.05.

Results and Discussion {#feb412722-sec-0008}
======================

Logistic model generated from a designed study does not meet the need for DRP on an increasing number of SNP‐related diseases {#feb412722-sec-0009}
-----------------------------------------------------------------------------------------------------------------------------

Logistic regression has been widely used for risk factor identification and evaluation, and is generally presented as follows:$$\text{Logit}{(P)} = \text{ln}{(\frac{P}{1 - P})} = \beta_{0} + \beta_{1}x_{1} + \beta_{i}x_{i}\ldots + \beta_{n}x_{n}$$ where β~*i*~ and *x* ~*i*~ are the coefficient and the logic value of each risk factor, respectively. Then, the disease risk *P* is expressed as follows:$$P = \frac{1}{1 + e^{- (\beta_{0} + \beta_{1}x_{1} + \beta_{i}x_{i}\ldots + \beta_{n}x_{n})}}.$$

In a research study, researchers usually use a majority of their experimental data to estimate the coefficients in Eqns ([1](#feb412722-disp-0001){ref-type="disp-formula"},[2](#feb412722-disp-0002){ref-type="disp-formula"}) by using statistical software through a maximum likelihood estimation algorithm [12](#feb412722-bib-0012){ref-type="ref"}. Then, the remaining experimental data are subjected to the generated logistic model for validation [12](#feb412722-bib-0012){ref-type="ref"}. Further, researchers can use the generalized model to predict the disease risk of new subjects. Apparently, this strategy is useful and effective for DRP based on the traditional risk factors [12](#feb412722-bib-0012){ref-type="ref"}.

In general, only one or a few novel SNP risk factors related to a disease are identified in a specific GWAS, in which the coefficients are determined and a specific logistic model is generated as described above. If the disease is linked to only these SNP risk factors, the logistic model generated from this GWAS is suitable for DRP directly. However, most human diseases are usually linked to a large number of SNP risk factors (sometimes up to 100 [17](#feb412722-bib-0017){ref-type="ref"}), and each of them has a minor effect on the disease risk. In particular, these SNPs are identified one by one by different research groups and are thus timely reported in multiple publications. Accordingly, the logistic models generated in these studies are different and are not interchangeable for DRP directly.

Generation of the logistic model for DRP by directly using multiple SNPs from multiple publications {#feb412722-sec-0010}
---------------------------------------------------------------------------------------------------

Now, the question is how to integrate the multiple SNPs from multiple publications to build a general model for DRP. Commercial DRP companies have developed algorithms to directly use the information of multiple SNPs from multiple publications for DRP by incorporating the OR value and the population frequency of each SNP, which are usually available in the GWAS literature and/or public databases. These algorithms, however, are complicated and lead to discrepant DRP results [8](#feb412722-bib-0008){ref-type="ref"}, [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"}, [11](#feb412722-bib-0011){ref-type="ref"}. We thought to integrate the multiple SNP risk factors from multiple publications into a logistic model for DRP (as indicated by Eqn [2](#feb412722-disp-0002){ref-type="disp-formula"}).

Regarding Eqn [2](#feb412722-disp-0002){ref-type="disp-formula"} for DRP, we need the coefficient β~*i*~ of each SNP and the constant coefficient β~0~, as well as the value of *x* ~*i*~ for each SNP that can be determined by the SNP genotyping of the subject. One way to determine β~*i*~ and β~0~ is to resequence the known SNP risk factors in a large number of subjects and then perform a logistic regression analysis. This strategy, although used previously [5](#feb412722-bib-0005){ref-type="ref"}, does not make full use of the knowledge of the SNP risk factors that have been reported and thus has compromised cost‐effectiveness. In particular, if a new SNP risk factor related to the disease is discovered, an additional clinical study needs to be performed for its incorporation into the logistic model.

In our approach, β~*i*~ in Eqn ( [2](#feb412722-disp-0002){ref-type="disp-formula"}) is not estimated by a statistical analysis on the clinical data as performed by Ripatti *et al*. [5](#feb412722-bib-0005){ref-type="ref"}. Rather, it is obtained directly by transforming the reported OR value of the SNP according to the logistic regression as follows:$$\beta_{i} = \text{ln}{(\text{OR}_{i})}$$

This is based on the definition of OR in a logistic regression model as follows:$$\text{OR}_{i} = \frac{\text{odds}(x_{i} + 1)}{\text{odds}(x_{i})} = \frac{\frac{P(x_{i} + 1)}{1 - P(x_{i} + 1)}}{\frac{P(x_{i})}{1 - P(x_{i})}} = \frac{e^{\beta_{0} + \beta_{1}x_{1} + \beta_{i}x_{i} + \beta_{i} + \ldots + \beta_{n}x_{n}}}{e^{\beta_{0} + \beta_{1}x_{1} + \beta_{i}x_{i} + \ldots + \beta_{n}x_{n}}} = e^{\beta_{i}}$$where the OR value of a SNP risk factor is explained as the ratio of the relative disease risk of the person at risk to the relative disease risk of a person not at risk.

Next, β~0~ can be determined as follows: if a SNP risk factor plays a role in the disease development, its contribution with respect to individuals should be considered the same as that with respect to populations. Then, Eqn [1](#feb412722-disp-0001){ref-type="disp-formula"} for an individual can be converted to the following form for populations:$$\text{ln}\left( \frac{P_{0}}{1 - P_{0}} \right) = \beta_{0} + \beta_{1}f_{1} + \beta_{i}f_{i}\ldots + \beta_{n}f_{n}$$where the population frequency (*f* ~*i*~) of each SNP and the average population disease risk (*P* ~0~) are usually available in public databases; the coefficient (β~*i*~) of each SNP has been already determined through Eqn [3](#feb412722-disp-0003){ref-type="disp-formula"}. Then, β~0~ can be calculated using Eqn [6](#feb412722-disp-0006){ref-type="disp-formula"} as follows:$$\beta_{0} = \text{ln}\left( \frac{P_{0}}{1 - P_{0}} \right) - {(\beta_{1}f_{1} + \beta_{i}f_{i}\ldots + \beta_{n}f_{n})}$$

Apparently, β~0~ reflects the contribution of the unidentified and/or unselected SNP risk factors, as well as of the non‐SNP risk factors, including the traditional risk factors (e.g., smoking and drinking). Importantly, if new critical SNPs are identified and need to be incorporated into our model, β~0~ can be recalculated according to Eqn [(6)](#feb412722-disp-0006){ref-type="disp-formula"}. In other words, our logistic model for DRP can be updated quickly if necessary.

In addition, the variance of *P* for each subject is collectively determined by the sum of the product of the variance of each β~*i*~ and the logic value *x* ~*i*~ (according to Eqn [2](#feb412722-disp-0002){ref-type="disp-formula"}), with the variance of each β~*i*~ being derived from the variance of OR for each SNP (according to Eqn [3](#feb412722-disp-0003){ref-type="disp-formula"}). In this regard, OR with a smaller variance is favorable when multiple ORs are available for a specific SNP as reported in multiple publications.

Equations [(1)](#feb412722-disp-0001){ref-type="disp-formula"}, [(2)](#feb412722-disp-0002){ref-type="disp-formula"}, [(3)](#feb412722-disp-0003){ref-type="disp-formula"}, [(4)](#feb412722-disp-0004){ref-type="disp-formula"}, [(5)](#feb412722-disp-0005){ref-type="disp-formula"}, [(6)](#feb412722-disp-0006){ref-type="disp-formula"} represent a general approach to establishing a logistic model‐based DRP algorithm by combining multiple SNPs from multiple publications, as summarized here. First, the SNP risk factor markers for a specific disease are selected from the existing GWAS literature, collecting their OR values and population frequencies. Second, the coefficient β~*i*~ of each SNP and the constant coefficient β~0~ are determined using Eqns [3](#feb412722-disp-0003){ref-type="disp-formula"} and [6](#feb412722-disp-0006){ref-type="disp-formula"}, respectively; therefore, Eqn [2](#feb412722-disp-0002){ref-type="disp-formula"} for DRP is ready. Third, the SNP risk factors for the subject are determined experimentally. Fourth, DRP is performed using Eqn [(2)](#feb412722-disp-0002){ref-type="disp-formula"}. Note that both homozygous and heterozygous SNPs are suitable for DRP in our algorithm. If the OR value for the homozygous form of a SNP is available, it is considered a dummy variable and *x* ~*i*~ is set as ln(OR~homozygous~)/ln(OR~heterozygous~).

Collection of SNP markers for lung cancer risk prediction in Chinese individuals {#feb412722-sec-0011}
--------------------------------------------------------------------------------

Thus far, about 400 000 reference SNPs have been deposited for human genomes (refer to the National Center for Biotechnology Information SNP database: <https://www.ncbi.nlm.nih.gov/snp/docs/RefSNP>\_about/). Of these, about 71 600 SNPs have been found to be associated with human diseases and traits, as reported in the NHGRI‐EBI GWAS Catalog database [18](#feb412722-bib-0018){ref-type="ref"}, [19](#feb412722-bib-0019){ref-type="ref"} ( <https://www.ebi.ac.uk/gwas/>). Lung cancer is considered a partially inherited complex disease [4](#feb412722-bib-0004){ref-type="ref"}, and about 80 SNPs have been reported to be associated with it [17](#feb412722-bib-0017){ref-type="ref"}. Among these SNPs, a threshold value of 1.15 was set subjectively, and some genetically dependent SNPs were omitted. In the end, eight representative SNPs were selected for the lung cancer risk prediction in our study. The OR value and the population frequency for each of these eight SNPs in Chinese individuals were collected (Table [1](#feb412722-tbl-0001){ref-type="table"}).

Generation of algorithms for lung cancer risk prediction {#feb412722-sec-0012}
--------------------------------------------------------

Then, we determined β for each SNP (Table [1](#feb412722-tbl-0001){ref-type="table"}) according to the aforementioned rules. Given the lifetime risk for lung cancer in Chinese men and women being 5.62% and 2.56%, respectively, β~0~ was calculated as −3.742 and −4.560 (for details, refer to Table [1](#feb412722-tbl-0001){ref-type="table"}). Together, the SNP‐based risk prediction for lung cancer with Chinese men and women was finalized as follows:$$P{(\text{men})} = 1/{(1 + e^{3.742 - 0.399x_{1} - 0.604x_{2} - 0.285x_{3} - 0.262x_{4} - 0.270x_{5} - 0.166x_{6} - 0.199x_{7} - 0.148x_{8}})}$$ $$P{(\text{women})} = 1/{(1 + e^{4.560 - 0.399x_{1} - 0.604x_{2} - 0.285x_{3} - 0.262x_{4} - 0.270x_{5} - 0.166x_{6} - 0.199x_{7} - 0.148x_{8}})}$$

Utilization of the algorithm for lung cancer risk prediction in Chinese individuals {#feb412722-sec-0013}
-----------------------------------------------------------------------------------

To demonstrate the effectiveness of our logistic algorithm, we collected blood samples of 48 Chinese subjects (38 men and 10 women), genotyped the eight selected SNPs (for details, refer to Table [S1](#feb412722-sup-0002){ref-type="supplementary-material"}) and then calculated the lung cancer risk of each subject by using Eqns ([7](#feb412722-disp-0007){ref-type="disp-formula"},[8](#feb412722-disp-0008){ref-type="disp-formula"}). Remarkably, subject 17, who was diagnosed as the sole lung cancer patient among these 48 subjects and had the symptoms of poorly differentiated adenocarcinoma in the right lung and multiple metastases, had the highest absolute lifetime risk of 28.3% and a relative lifetime risk of 5.0 (Table [2](#feb412722-tbl-0002){ref-type="table"}). The absolute lifetime risk of this patient was significantly higher than that of the remaining 47 persons (*P *=* *0.0000024) and was significantly higher than that of the remaining 37 men (*P *=* *0.000015). In addition, the average lifetime risk for the 38 men and the 10 women was 8.9% and 5.5%, respectively (Table [2](#feb412722-tbl-0002){ref-type="table"}); both of these values were not significantly different from the average disease risk of men and women (*P *\>* *0.05).

###### 

Lung cancer risk and clinical symptoms for 48 subjects.

  ID   Absolute risk   Relative risk   Sex   Symptom
  ---- --------------- --------------- ----- -----------------------------------------------------------------------------
  17   0.283           5.0             M     Poorly differentiated adenocarcinoma in the right lung, multiple metastases
  23   0.174           3.1             M     Normal
  27   0.174           3.1             M     Normal
  25   0.152           2.7             M     Normal
  26   0.145           2.6             M     Normal
  16   0.141           2.5             M     Normal
  2    0.138           2.5             M     After surgery for the right knee ligament reconstruction
  32   0.122           2.2             M     Normal
  22   0.119           2.1             M     Normal
  24   0.119           2.1             M     Normal
  19   0.094           1.7             M     Normal
  4    0.092           1.6             M     Lumbar spinal stenosis
  10   0.092           1.6             M     Lumbar disc herniation
  11   0.092           1.6             M     Normal
  30   0.087           1.5             M     Normal
  28   0.086           3.4             F     Non‐Hodgkin\'s lymphoma
  15   0.084           1.5             M     Normal
  43   0.081           1.4             M     Normal
  18   0.081           3.2             F     Tubal pregnancy
  33   0.078           1.4             M     Normal
  8    0.077           1.4             M     Normal
  31   0.077           3.0             F     Cholecystitis
  9    0.076           1.3             M     Normal
  34   0.073           1.3             M     Normal
  1    0.072           1.3             M     Normal
  47   0.072           1.3             M     Normal
  38   0.071           1.3             M     Nasopharyngeal
  21   0.069           2.7             F     Right breast invasive ductal carcinoma, appendicitis
  14   0.067           2.6             F     Intrauterine pregnancy
  48   0.064           1.1             M     Normal
  40   0.063           1.1             M     Normal
  12   0.061           1.1             M     Normal
  29   0.058           2.3             F     After surgery for the right shoulder
  42   0.056           1.0             M     Normal
  20   0.054           1.0             M     Normal
  39   0.053           0.9             M     Normal
  37   0.044           0.8             M     Normal
  6    0.042           0.8             M     Normal
  3    0.040           0.7             M     Intertrochanteric fracture of the left femur
  41   0.040           0.7             M     Normal
  44   0.040           0.7             M     Normal
  46   0.040           1.6             F     Normal
  35   0.038           0.7             M     Normal
  7    0.035           0.6             M     Normal
  45   0.035           0.6             M     Normal
  5    0.035           1.4             F     Abnormal ampulla of Vater (likely to be malignant)
  13   0.022           0.8             F     Hemorrhoids and ovarian cysts, bronchial asthma
  36   0.019           0.7             F     Osteoarthritis knees
  N1   0.162           6.3             F     Non‐small‐cell lung cancer in the right lung
  N2   0.040           0.7             M     Normal
  N3   0.056           1.0             M     Normal
  N4   0.081           1.4             M     Normal
  N5   0.040           0.7             M     Normal
  N6   0.035           0.6             M     Normal
  N7   0.040           1.6             F     Normal
  N8   0.072           1.3             M     Normal
  N9   0.064           1.1             M     Normal
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In another batch of genetic screening for nine subjects, we found that a female patient diagnosed with non‐small‐cell lung cancer had an absolute lifetime risk of 16.2% and a relative lifetime risk of 6.3 (Table [2](#feb412722-tbl-0002){ref-type="table"}), which was significantly higher than that of the remaining eight normal subjects. These results, although based on a test with a small group size and a limited number of positive patients, indicated that our algorithm was sensitive, to a certain degree, in screening the high‐risk lung cancer patient.

Conclusions {#feb412722-sec-0014}
===========

In this study, we developed a general logistic model‐based algorithm to calculate the disease risk by directly using multiple SNP risk factors from multiple publications, and tested this algorithm on Chinese individuals for lung cancer risk prediction. The logistic algorithm that we explored was apparently more intuitive and self‐evident than the algorithms adopted by commercial DRP providers [7](#feb412722-bib-0007){ref-type="ref"}, [8](#feb412722-bib-0008){ref-type="ref"}, [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"}, [11](#feb412722-bib-0011){ref-type="ref"}, although similar input parameters were used [9](#feb412722-bib-0009){ref-type="ref"}, [10](#feb412722-bib-0010){ref-type="ref"} (i.e., the average population risk of disease, the OR value and the genotype and/or allele frequencies of the SNPs).

Our logistic algorithm had several advantages: (a) the coefficient β in the risk calculation equation directly reflected the contribution of each SNP and was simply determined by the OR value; (b) the SNP risk factor markers and the OR value were adjustable and/or promptly updated if necessary, such that β~0~ could be recalculated using the new set of SNP markers; (c) the SNP risk factor markers, with or without the OR value for the homozygous forms, were all suitable for risk prediction; and (d) accordingly, the non‐SNP risk factors (e.g., smoking and drinking) could also be included in our logistic model for DRP. Therefore, our study is of interest for the commercialization of DRP, given that similar logistic model‐based algorithms can be established for common complex diseases (e.g., diabetes, cardiovascular disease and cancers) that have been reported to be linked quantitatively to multiple SNP risk factors [17](#feb412722-bib-0017){ref-type="ref"}.
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